Smartwatch with heart rate monitor icon on colorful diagonal striped background
Medtech Case Study

Embedding Patient Engagement Across Functions in a Life Sciences Company

Servier Establishes a Patient Expert Research and Development Board to Embed Patient-Centric Culture Across Company
 

Source
Research Involvement and Engagement

Link
Embedding Patient Engagement in the R&D Process of a Life Sciences Company Through Co-Creation with a Patient Expert R&D Board: A Case Study
 

Description of Case Study

This case describes Servier’s efforts to partner with a patient consultancy and 18 patient experts from across Europe to form a patient advisory board that cocreated projects, informed clinical trial design, and prioritized research initiatives. Patient engagement occurred primarily through cocreation workshops, advisory board discussions, and structured collaboration, enabling patients to shape early-stage research and development (R&D) strategy and improve trial design and patient experience. The purpose of this engagement was to embed patients’ voices into the company’s R&D processes and culture, ensuring research priorities, study design, and innovation efforts better reflect patient needs and perspectives.
 

Quick Facts

Organization name: Servier
Organization type: pharmaceutical company
Product category: pharmaceutical/biological product
Region(s) of patient engagement activities: Europe: Austria, Belgium, France,
Germany, Ireland, Italy, Portugal, Spain, Switzerland, United Kingdom
Total product life cycle stage(s): discovery/preclinical; clinical/testing; adoption

 

Product Type(s)

  • pharmaceutical/biological product
     

Product Medical Specialty Area(s)

  • multiple therapeutic areas (10 disease areas represented)
     

Stakeholders

  • pharmaceutical company: internal discovery/R&D teams
  • pharmaceutical company: internal R&D/clinical affairs teams
  • pharmaceutical company: internal compliance teams
  • patients and caregivers, patient organizations
  • other: European Patients; Academy on Therapeutic Innovation
     

Methods and Sources of Patient Input

  • patient advisory boards
  • patient advocacy organizations
  • interviews/focus groups/surveys
  • human-centered design methodologies
  • patient-driven research agendas and investments
  • patient-sensitive design controls
  • other: patient storytelling
  • other: training programs
     

Impact of Patient Engagement

The patient engagement effort led to the cocreation of five concrete project areas and working groups, shaping R&D processes such as patient advisory structures, decentralized clinical trial design, and internal training programs. It also contributed to a broader cultural shift within the company toward patient-centric R&D, increasing staff awareness, cross-company buy-in, and integration of patient perspectives into decision-making. More broadly, the collaboration generated practical lessons and frameworks for engaging patients in the life sciences, demonstrating a scalable model for embedding patient input into research strategy and organizational practices.
 

Lessons Learned

The authors provide a list of lessons learned in Table 3 of the publication. Below is a summary of some of the key lessons learned:

  • Up-front planning and resource allocation are critical: Running a patient board requires considerable investment in internal expertise, time, and funds, and these need to be anticipated and allocated before the collaboration begins rather than managed reactively.
  • Cross-company buy-in requires sustained effort: Since a patient board is not directly linked to a specific therapeutic product or project, staff may need to extend beyond their normal responsibilities; drawing connections to the organization's priorities and strategy and securing leadership buy-in are essential to maintaining momentum and ensuring sustainability.
  • Defining and measuring value is a genuine challenge: Translating patient engagement into tangible, measurable impact on R&D processes can be difficult, and teams should set realistic expectations about when and how value will be measured, in both the short and long term.
  • Trust and transparency must be built deliberately: The article emphasizes the need to identify and contract patient partners carefully, clarifying roles and responsibilities, ensuring a variety of perspectives, managing expectations honestly, and maintaining ongoing communication as the engagement evolves.
  • International compliance challenges: Fostering meaningful patient engagement in different geographies required balancing structured, predefined meeting agendas with opportunities for open discussion; providing transparent feedback on how patient input would be used; and establishing consistent internal procedures for working with patient experts across diverse regulatory environments.